Peripheral arterial disease is prevalent and reflects overall cardiovascular disease state. Best medical treatment is the cornerstone of management to reduce peripheral arterial disease symptoms and to minimize vascular morbidity and mortality. The aim of this study was to assess the prescription practice of general practitioners in Northern Ireland for patients with peripheral arterial disease. All general practitioners were from the Northern Ireland Professional Medical Directory, and a questionnaire was used to determine the prescribing patterns for peripheral arterial disease. In all, 468 general practitioners responded; 94% prescribed aspirin to nondiabetic patients, and 44.9% prescribed statin, with similar results for diabetic patients. Angiotensin-converting enzyme inhibitors, multivitamins, and β-blockers were not often prescribed. Statin was prescribed to patients with diabetic peripheral arterial disease at a lower cholesterol concentration. In all, 52% would consider statin and fibrate together. Budgetary consideration influenced 6%. Northern Ireland general practitioners are reluctant to prescribe medication that is effective in the secondary prevention of vascular morbidity and mortality in high-risk patients.
Cox GS, Hertzer NR, Young JR, et al. Nonoperative treatment of superficial femoral artery disease: long-term follow up. J Vasc Surg. 1993;17:172-182.
4.
Cronenwett JL , Warner KG, Zelenock GB, et al. Intermittent claudication. Arch Surg.1984;119:430-436.
5.
Dormandy JA, Heeck L., Vig S.Lower-extremity atherosclerosis as a reflection of a systemic process: implications for concomitant coronary and carotid disease. Semin Vasc Surg . 1999;12:118-122.
6.
Dormandy JA, Heeck L., Vig S.Peripheral arterial occlusive disease. Clinical data for decision-making. Semin Vasc Surg. 1999;12:93-162.
7.
Dormandy JA, Heeck L., Vig S.The natural history of claudication: risk to life and limb. Semin Vasc Surg. 1999;12:123-137.
8.
Hankey GJ, Norman PE, Eikelboom JWMedical treatment of peripheral arterial disease. JAMA. 2006;295: 547-553.
Daskalopoulou SS, Daskalopoulos ME, Liapis CD, et al. Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality . Curr Med Chem. 2005;12:443-452.
11.
Kroger K.Dyslipoproteinemia and peripheral arterial occlusive disease. Angiology. 2004;55:135-138.
12.
Hirsch AT, Gotto AM Jr.Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction. Vasc Med. 2002;7:323-331.
13.
Hertzer NR, Young JR, Kramer JR, et al. Routine coronary angiography prior to elective aortic reconstruction: results of selective myocardial revascularization in patients with peripheral vascular disease. Arch Surg. 1979;114:1336-1344.
14.
Eagle KA, Rihak CS, Foster ED, et al. Long-term survival in patients with coronary artery disease: importance of peripheral vascular disease. The Coronary Artery Surgery Study (CASS) Investigation. J Am Coll Cardiol.1994 ;5:1091-1095.
15.
Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;303:81-106.
Scottish Intercollegiate Guidelines Network (SIGN).Secondary Prevention of Coronary Heart Disease Following Myocardial Infarction. Edinburgh, Scotland: Royal College of Physicians; 2000.
18.
Department of Health.National Service Framework for Coronary Heart Disease - Modern Standards and Service Models. London, United Kingdom: Department of Health; 2000.
19.
British Medical Association and the Royal Pharmaceutical Society of Great Britain.British National Formulary. London, United Kingdom: British Medical Association and the Royal Pharmaceutical Society of Great Britain; 2003.
20.
CAPRIE Steering Committee.A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
21.
Shaya FT, El Khoury AC, Mullins CS, et al. Drug therapy persistence and stroke recurrence. Am J Manag Care.2006;12:313-319.
22.
Straus SE, Majumdar SR, McAlister FANew evidence for stroke prevention: scientific review. JAMA . 2002;288:1388-1395.
23.
Yusuf S., Zhao F., Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med.2001;345:494-502.
24.
Steinhubl SR , Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA.2002;288:2411-2420.
25.
Fox KA, Mehta SR, Peters R., et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable Angina to Prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004;110:1202-1208.
26.
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Trial Investigators.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med.2001;345:494-502.
27.
Diener HC, Bogousslavsky J., Brass LM, et al; on behalf of the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331-337.
28.
Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with a history of diabetes. Am J Cardiol.2002;90:625-628.
29.
Bhatt DL, Chew DP, Hirsch AT, et al. Superiority of clopidogrel versus aspirin in patients with a history of previous cardiac surgery. Circulation. 2001;103:363-368.
30.
Goldberg RB , Mellies MJ, Sacks FM, et al; for CARE investigators.Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. Circulation. 1998;98:2513-2519.
31.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med.1998;339:1349-1357.
32.
Heart Protection StudyCollaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
33.
Heart Protection Study Collaborative Group.Effects of cholesterol lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2002 ;363:757-767.
34.
Heart Protection StudyCollaborative Group.MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361:2005-2016.
35.
Colhoun HM, Betteridge DJ, Durrington PN; on behalf of the CARDS investigators.Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696.
36.
National Institute for Clinical Excellence.Statins for prevention of cardiovascular events. National Guideline Clearing-house Website. http://www.nice.org.uk . Accessed April 2006.
37.
Sacks FM; for Expert Group on HDL cholesterol.The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert Group recommendations. Am J Cardiol.2002;90:139-143.
38.
Manninen V. , Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA.1998;260:641-651.
39.
Rubins HBRobins SJ, Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med.1999;341:410-418.
40.
The UK HDL-C Consensus Group.Role of fibrates in reducing coronary risk: a UK Consensus. Curr Med Res Opin. 2004;20:241-247.
41.
Williams B. , Poulter NR, Brown MJ, et al. British Hypertension Society. Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens. 2004;18:139-185.
42.
Yusuf S., Sleight P., Pogue J., et al. The HOPE (Heart Outcomes Prevention Evaluation) study investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med.2000;342:145-153.
43.
Hippisley-Cox J., Coupland C.Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease, nested case-control analysis . Br Med J. 2005;330:1059-1063.
44.
Montgomery AA, Fahey T., Harding J., et al. The influence of absolute cardiovascular risk, patient utilities and costs on the decision to treat hypertension: a Markov decision analysis. J Hypertens. 2003 ;21:1753-1759.
45.
Wald NJ, Law MRA strategy to reduce cardiovascular disease by more than 80%. Br Med J. 2003;326:1419.
